Broadcast Date: 
  • Time: 

Many biotech and pharmaceutical companies focused on mRNA manufacturing experience challenges associated with their plasmid DNA (pDNA) supply, including slow or delayed production and poor or inconsistent DNA quality, impacting their ability to meet timelines.

In this webinar, presenters Benyamin Panah, PhD, RNA subject matter expert, Touchlight, and Scott Alderucci, director of process development, Curia, will address the evolving challenges of pDNA in mRNA manufacture, and discuss an alternative to pDNA—an enzymatic, antibiotic-free DNA vector called doggybone DNA (dbDNA™). The webinar will outline how Touchlight and Curia are combining Touchlight’s dbDNA platform with Curia’s mRNA manufacturing capability to bring a rapid, reliable and high-quality solution to the market.


A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.


Produced with support from:

Touchlight logo
Scott Alderucci
Scott Alderucci
Director of Process Development
Benyamin Panah
Benyamin Panah, PhD
RNA Subject Matter Expert
Previous articleNew Type of Brain Cell Could Represent Targets for Protective CNS Therapies
Next articleRecipharm and Ahead Therapeutics to Develop and Manufacture Novel Therapy for Myasthenia Gravis